Hematology at Shanghai First People's Hospital | CMCS

Expert Blood Cancer & Hematological Disease Care at One of Shanghai's Premier Academic Medical Centers

The Department of Hematology at Shanghai First People's Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of Shanghai's most distinguished hematology centers, with a national reputation for excellence in the treatment of leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, bone marrow failure, and the management of complex hematological conditions. With a comprehensive stem cell transplantation program and access to CAR-T cell therapy, the department combines outstanding clinical expertise with a world-class research program, offering international patients access to some of China's most eminent hematologists. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their hematological care journey.

About the Department

The hematology department is a national key clinical specialty operating dedicated hematology inpatient wards with HEPA-filtered laminar flow rooms, a bone marrow transplantation unit (BMT), a hematology day unit for outpatient chemotherapy and infusions, a flow cytometry laboratory, a molecular diagnostics laboratory, a cytogenetics laboratory, a CAR-T cell therapy program, and works in close collaboration with oncology, radiation oncology, and infectious disease through a fully integrated multidisciplinary hematology tumor board.

Leukemia

Acute Myeloid Leukemia (AML)

• Intensive Induction — 7+3 (cytarabine + daunorubicin/idarubicin); CPX-351 (liposomal daunorubicin + cytarabine) for therapy-related AML and AML-MRC; FLAG-IDA; high-dose cytarabine consolidation
• Targeted Therapy — Midostaurin + chemotherapy for FLT3-mutated AML; quizartinib for FLT3-ITD AML; gilteritinib for relapsed/refractory FLT3-mutated AML; enasidenib for IDH2-mutated AML; ivosidenib for IDH1-mutated AML; olutasidenib; venetoclax + azacitidine for unfit patients (VIALE-A); glasdegib + LDAC
• Gemtuzumab Ozogamicin (GO) — For CD33-positive AML; fractionated dosing with 7+3; monotherapy for relapsed/refractory
• Allogeneic SCT — For intermediate and high-risk AML in CR1; matched sibling and unrelated donor; haploidentical transplant (Beijing protocol); cord blood transplant
• Measurable Residual Disease (MRD) — Flow cytometry and PCR-based MRD monitoring; MRD-guided treatment decisions; post-transplant MRD surveillance

Acute Lymphoblastic Leukemia (ALL)

• Ph-Negative ALL — Pediatric-inspired regimens (CALGB 10403, GRAALL); hyper-CVAD; MRD-guided therapy; blinatumomab for MRD-positive ALL; inotuzumab ozogamicin for relapsed/refractory B-ALL
• Ph-Positive ALL — TKI + chemotherapy (ponatinib, dasatinib); blinatumomab + ponatinib (GIMEMA LAL2116); allogeneic SCT for high-risk; asciminib for T315I mutation
• T-ALL — Nelarabine-containing regimens; bortezomib; gamma-secretase inhibitors for NOTCH1-mutated T-ALL
• CAR-T Cell Therapy — Tisagenlecleucel (Kymriah) for relapsed/refractory B-ALL in children and young adults; axicabtagene ciloleucel; lisocabtagene maraleucel; one of Shanghai's most experienced CAR-T programs
• CNS Prophylaxis & Treatment — Intrathecal chemotherapy; CNS-directed systemic therapy; cranial radiation for CNS relapse

Chronic Myeloid Leukemia (CML)

• TKI Therapy — Imatinib; dasatinib; nilotinib; bosutinib; ponatinib for T315I and high-risk; asciminib (STAMP inhibitor) for any-line CML; treatment-free remission (TFR) attempt after deep molecular response
• Blast Crisis — TKI + intensive chemotherapy; allogeneic SCT; venetoclax combinations
• Molecular Monitoring — BCR-ABL1 PCR (IS); major molecular response (MMR); deep molecular response (MR4, MR4.5); mutation analysis for TKI resistance

Chronic Lymphocytic Leukemia (CLL)

• BTK Inhibitors — Ibrutinib; acalabrutinib; zanubrutinib (superior tolerability); pirtobrutinib (non-covalent) for BTK inhibitor-resistant CLL
• BCL-2 Inhibitors — Venetoclax + obinutuzumab (CLL14); venetoclax + ibrutinib; fixed-duration venetoclax-based therapy
• High-Risk CLL — TP53 mutation/del(17p): BTK inhibitor preferred; del(11q); complex karyotype; allogeneic SCT for selected high-risk patients
• Richter Transformation — R-CHOP; pirtobrutinib; epcoritamab; CAR-T for eligible patients

Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)

• First-Line — R-CHOP; polatuzumab vedotin + R-CHP (pola-R-CHP — POLARIX trial) for IPI ≥2; CNS prophylaxis for high-risk; consolidative ASCT for high-risk
• Relapsed/Refractory — CAR-T cell therapy: axicabtagene ciloleucel (Yescarta); lisocabtagene maraleucel (Breyanzi); tisagenlecleucel; loncastuximab tesirine; epcoritamab (subcutaneous bispecific); glofitamab (bispecific); odronextamab; mosunetuzumab
• Double/Triple Hit Lymphoma — DA-EPOCH-R; CNS prophylaxis; consolidative ASCT; CAR-T for relapsed disease

Follicular Lymphoma

• First-Line — R-CHOP; BR (bendamustine + rituximab); obinutuzumab + chemotherapy; rituximab maintenance; watch-and-wait for low tumor burden
• Relapsed/Refractory — Mosunetuzumab; epcoritamab; CAR-T (axicabtagene ciloleucel for grade 3B); tazemetostat for EZH2-mutated FL; PI3K inhibitors (copanlisib, umbralisib)

Hodgkin Lymphoma

• First-Line — ABVD; BV-AVD (brentuximab vedotin + AVD) for advanced stage; PET-adapted therapy; involved-site radiation therapy (ISRT)
• Relapsed/Refractory — Brentuximab vedotin; pembrolizumab; nivolumab; ASCT for chemosensitive relapse; allogeneic SCT for post-ASCT relapse

T-Cell Lymphomas

• PTCL — CHOP; CHOEP; BV-CHP for CD30-positive PTCL; romidepsin; pralatrexate; belinostat; mogamulizumab for CTCL/ATLL; ASCT for eligible patients
• CTCL (Mycosis Fungoides/Sézary) — Skin-directed therapy; mogamulizumab; brentuximab vedotin for CD30-positive MF; romidepsin; ECP (extracorporeal photopheresis)
• NK/T-Cell Lymphoma — SMILE; P-GEMOX; asparaginase-based regimens; pembrolizumab for relapsed disease; ASCT for eligible patients

Multiple Myeloma

• Newly Diagnosed (Transplant-Eligible) — Daratumumab + VRd (Dara-VRd — PERSEUS trial); isatuximab + VRd; bortezomib + lenalidomide + dexamethasone (VRd); ASCT; lenalidomide maintenance; MRD-guided therapy
• Newly Diagnosed (Transplant-Ineligible) — Daratumumab + VRd; daratumumab + VMP; daratumumab + Rd; ixazomib + Rd
• Relapsed/Refractory — Carfilzomib; pomalidomide; elotuzumab; selinexor; belantamab mafodotin; teclistamab (BCMA x CD3 bispecific); talquetamab (GPRC5D x CD3 bispecific); elranatamab; ciltacabtagene autoleucel (Carvykti — CAR-T); idecabtagene vicleucel (Abecma — CAR-T)
• Smoldering Myeloma — Daratumumab monotherapy for high-risk SMM (AQUILA trial); observation for low-risk

Myelodysplastic Syndromes (MDS)

• Lower-Risk MDS — ESA (epoetin alfa, darbepoetin); luspatercept (Reblozyl) for ring sideroblasts and SF3B1-mutated MDS; lenalidomide for del(5q); transfusion support; iron chelation
• Higher-Risk MDS — Azacitidine; decitabine; venetoclax + azacitidine; imetelstat for transfusion-dependent MDS; allogeneic SCT for eligible patients
• MDS with TP53 mutation — Eprenetapopt (APR-246) + azacitidine; magrolimab + azacitidine; allogeneic SCT

Stem Cell Transplantation

• Autologous SCT (ASCT) — For multiple myeloma; lymphoma; high-dose melphalan; BEAM conditioning; one of Shanghai's most experienced ASCT programs
• Allogeneic SCT — Matched sibling donor (MSD); matched unrelated donor (MUD); haploidentical transplant (Beijing/GIAC protocol); cord blood transplant; myeloablative and reduced-intensity conditioning (RIC); post-transplant cyclophosphamide (PTCy) for GvHD prevention
• GvHD Management — Ruxolitinib for steroid-refractory acute GvHD (REACH2); ruxolitinib for chronic GvHD (REACH3); belumosudil; axatilimab; ibrutinib for chronic GvHD
• CAR-T Cell Therapy — One of Shanghai's most experienced CAR-T programs; tisagenlecleucel; axicabtagene ciloleucel; lisocabtagene maraleucel; ciltacabtagene autoleucel; idecabtagene vicleucel; leukapheresis coordination; bridging therapy; cytokine release syndrome (CRS) management; ICANS management

Benign Hematology

• Aplastic Anemia — Horse ATG + cyclosporine + eltrombopag; allogeneic SCT for severe AA in young patients; eltrombopagthrombopag; danazol for refractory cases
• ITP — Corticosteroids; IVIG; rituximab; TPO receptor agonists (eltrombopag, romiplostim, avatrombopag); fostamatinib; splenectomy for refractory ITP
• Hemophilia — Factor VIII and IX replacement; emicizumab (Hemlibra) for hemophilia A; fitusiran; concizumab; gene therapy coordination
• Thalassemia — Transfusion support; iron chelation; luspatercept for beta-thalassemia; allogeneic SCT; gene therapy (betibeglogene autotemcel — Zynteglo) coordination
• Sickle Cell Disease — Hydroxyurea; voxelotor; crizanlizumab; L-glutamine; allogeneic SCT; gene therapy (exagamglogene autotemcel — Casgevy — CRISPR-based) coordination

Why International Patients Choose Shanghai First People's Hospital Hematology

• CAR-T Cell Therapy — One of Shanghai's most experienced CAR-T programs; tisagenlecleucel, axicabtagene ciloleucel, ciltacabtagene autoleucel for leukemia, lymphoma, and myeloma
• Haploidentical Transplant — Beijing/GIAC protocol for haploidentical SCT; expands donor pool to virtually all patients
• Bispecific Antibodies — Teclistamab, talquetamab, epcoritamab, glofitamab for relapsed/refractory myeloma and lymphoma
• Pirtobrutinib for CLL/MCL — Non-covalent BTK inhibitor for BTK inhibitor-resistant disease
• MRD-Guided Therapy — Sensitive MRD monitoring for AML, ALL, and myeloma; treatment decisions guided by MRD status
• Cost-Effectiveness — World-class hematological care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your hematological diagnosis, bone marrow biopsy reports, cytogenetics, molecular profiling, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate hematologist based on your condition — leukemia, lymphoma, myeloma, MDS, transplantation, or benign hematology.
4. MDT Submission — We facilitate pre-arrival case review by the multidisciplinary hematology tumor board.
5. Priority Scheduling — We secure a consultation with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near Shanghai First People's Hospital, and Shanghai airport transfers.
7. Treatment Coordination — Full coordination of chemotherapy, targeted therapy, CAR-T cell therapy, or stem cell transplantation scheduling.
8. Post-Treatment Follow-Up — Treatment report translation, MRD result interpretation, and remote follow-up coordination after you return home.

Book a Consultation

If you have leukemia, lymphoma, multiple myeloma, MDS, aplastic anemia, or a complex hematological condition — CMCS can arrange a specialist consultation with Shanghai First People's Hospital's hematology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com